Compare Stocks → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ECONASDAQ:PHAR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECOOkeanis Eco Tankers$30.05+0.7%$0.00$20.00▼$32.46N/AN/A56,925 shs15,528 shsPHARPharming Group$10.84-0.1%$11.59$9.70▼$16.71$728.11M0.172,870 shs1,164 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECOOkeanis Eco Tankers+0.64%+0.23%-3.75%+3,004,999,900.00%+3,004,999,900.00%PHARPharming Group+0.09%-1.45%-3.90%-4.75%-14.65%Top Project Outperforms BTC in 2023… (Ad)According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationECOOkeanis Eco TankersN/AN/AN/AN/AN/AN/AN/AN/APHARPharming Group2.6879 of 5 stars3.55.00.00.03.00.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECOOkeanis Eco TankersN/AN/AN/AN/APHARPharming Group3.00Buy$37.00241.33% UpsideCurrent Analyst RatingsLatest SAVP, ECO, FOG, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2024PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECOOkeanis Eco Tankers$413.10MN/AN/AN/AN/AN/APHARPharming Group$245.32M2.97$0.10 per share111.32$3.27 per share3.31Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECOOkeanis Eco TankersN/AN/A0.00∞N/AN/AN/AN/A5/30/2024 (Estimated)PHARPharming Group-$10.12M-$0.14N/AN/AN/A-4.13%-4.53%-2.15%5/9/2024 (Estimated)Latest SAVP, ECO, FOG, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023PHARPharming Group$0.05-$0.03-$0.08-$0.02$71.83 million$81.20 million2/29/202412/31/2023ECOOkeanis Eco Tankers$0.62$0.63+$0.01$0.60N/A$91.67 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthECOOkeanis Eco Tankers$2.648.79%N/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ALatest SAVP, ECO, FOG, and PHAR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/1/2024ECOOkeanis Eco Tankers--$0.663/8/20243/11/20243/22/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECOOkeanis Eco TankersN/AN/AN/APHARPharming Group0.624.163.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECOOkeanis Eco TankersN/APHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipECOOkeanis Eco TankersN/APHARPharming Group2.07%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableECOOkeanis Eco TankersN/AN/AN/AN/APHARPharming Group33267.11 million65.72 millionNot OptionableSAVP, ECO, FOG, and PHAR HeadlinesSourceHeadlinePharming Group (NASDAQ:PHAR) Shares Gap Up to $11.00americanbankingnews.com - March 24 at 6:22 AMPharming Group (NASDAQ:PHAR) Stock Price Down 5%marketbeat.com - March 19 at 4:49 PMPharming Group (NASDAQ:PHAR) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - March 18 at 5:10 PMPharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volumemarketbeat.com - March 18 at 11:25 AMUber to pay $178 million in Australia taxi class action settlementmsn.com - March 18 at 3:45 AMPharming Group (NASDAQ:PHAR) Expected to Post Q1 2024 Earnings of $0.01 Per Shareamericanbankingnews.com - March 18 at 1:28 AMPharming reports Q4 resultsmsn.com - March 15 at 7:46 PMPharming Group N.V. 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - March 14 at 9:06 AMPharming Group (NASDAQ:PHAR) Stock Price Down 6.5%marketbeat.com - March 13 at 3:39 PMPharming Group (NASDAQ:PHAR) Short Interest Up 900.0% in Februarymarketbeat.com - March 12 at 11:13 PMPharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14finanznachrichten.de - February 29 at 6:26 AMPharming Group N.V. (PHGN.F)finance.yahoo.com - February 20 at 3:10 PMPharming Group N.V.: Pharming Group to participate in February investor conferencesfinanznachrichten.de - February 8 at 3:55 AMPharming Group to participate in February investor conferencesfinance.yahoo.com - February 8 at 3:55 AMAstria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readoutseekingalpha.com - February 5 at 12:52 AMPharming Group: Strong Buy Rating on Robust Revenue Growth and Promising Clinical Pipeline Expansionmarkets.businessinsider.com - January 8 at 7:31 PMWhat's Going On With Netherlands-Based Biopharma Company Pharming Shares Today?msn.com - January 8 at 2:30 PMPharming Group issues full-year 2023 guidanceseekingalpha.com - January 8 at 5:14 AMPharming Stock (NASDAQ:PHAR) Dividends: History, Yield and Datesbenzinga.com - January 6 at 9:56 AMChief Information Security Officertweakers.net - January 1 at 7:34 AMBuy Rating Affirmed for Pharming Group Amid Promising Clinical Advances and FDA Feedbackmarkets.businessinsider.com - December 15 at 12:50 AMPharming To Develop Leniolisib For Additional PIDs Beyond APDS; Phase 2 Trial To Initiate In Q2markets.businessinsider.com - December 13 at 8:30 AMAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Pharming Group (PHAR)markets.businessinsider.com - December 13 at 1:33 AMPharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)finance.yahoo.com - December 13 at 1:33 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesYour Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank Stocks4 Stocks to Buy Before the Fed Cuts Interest RatesMarch 19, 2024 7:49 AMView 4 Stocks to Buy Before the Fed Cuts Interest Rates$5 Billion Boost for Taiwan Semiconductor Aids Nvidia ExpansionMarch 14, 2024 7:39 AMView $5 Billion Boost for Taiwan Semiconductor Aids Nvidia ExpansionHere's How to Dip into Chinese Stocks if You Live in the U.S.March 7, 2024 12:00 PMView Here's How to Dip into Chinese Stocks if You Live in the U.S.Nio Stock Could Double Your Money This Coming EV CycleMarch 4, 2024 6:04 AMView Nio Stock Could Double Your Money This Coming EV CycleAll Headlines Company DescriptionsOkeanis Eco TankersNYSE:ECOOkeanis Eco Tankers Corp., a tanker company, engages in the ownership, chartering and operation of oil tanker vessels worldwide. The company also provides various shipping services, such as technical support, maintenance, and insurance consulting services. It operates a fleet of six modern scrubber-fitted Suezmax tankers and eight modern scrubber-fitted VLCC tankers. The company was incorporated in 2018 and is based in Piraeus, Greece.Pharming GroupNASDAQ:PHARPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.